{"prompt": "['LINEBERGER COMPREHENSIVE CANCER CENTER', 'CLINICAL ONCOLOGY RESEARCH PROGRAM', 'April 2017', 'UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL', '(5) The four yes/no questions of the PTSS-14 have been removed, as the results', 'from these four questions are not used in calculating the total score, not', 'typically reported in the literature, and are more appropriate for ICU settings,', 'which the scale was originally designed for. This modification is reflected in', 'Appendix E and does not necessitate modification in other areas of the', 'protocol.', '(6) Section 5.2. Language added to explicitly reflect that the PI, primary medical', \"providers, or other emergency personnel may request unblinding of a subject's\", 'randomized treatment from the IDS pharmacy.', 'Therapy changes', '(1) Throughout the protocol, the preparation of our intervention was changed', 'from Thiamine 200 mg in a 2 mL syringe to Thiamine 200 mg diluted in 100', 'mL 0.9% normal saline. Our placebo was changed from 2 mL of 0.9%', 'normal saline to 100 mL 0.9% normal saline to maintain blinding. The', 'intervention will be administered over 30 minutes, rather than the four', 'minutes described in the previous version of this protocol. No changes were', 'made to strength, route (intravenous), frequency (TID), or duration (seven', 'days). This modification was made to improve nursing workflow, as it is not', 'practical for them to administer the syringe by hand at 50 mg/min as outlined', 'in the previous version of the protocol. This modification in no way increases', 'risk to subjects.', 'THE ATTACHED VERSION DATED 9/14/17 INCORPORATES THE ABOVE', 'REVISIONS', 'ATTACH TO THE FRONT OF EVERY COPY OF PROTOCOL']['LINEBERGER COMPREHENSIVE CANCER CENTER', 'CLINICAL ONCOLOGY RESEARCH PROGRAM', 'April 2017', 'UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL', 'LCCC 1726:', 'Randomized Placebo Controlled Trial of High Dose Intravenous Thiamine for the', 'Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation', 'Short Title: High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic', 'Hematopoietic Stem Cell Transplantation', 'Principal Investigator', 'Zev Nakamura, MD', '101 Manning Drive', 'Campus Box 7160', 'Chapel Hill, NC 27599', '984-974-3829 (PHONE)', '984-974-9646 (FAX)', 'Email: zev_nakamura@med.unc.edu', 'Medical Monitor', 'Zev Nakamura, MD', '984-974-3829 (PHONE)', '919-216-3157 (PAGER)', 'Email: zev_nakamura@med.unc.edu', 'Co-Investigator(s)', 'Donald Rosenstein, MD', \"3134 Physician's Office Building\", '170 Manning Drive', 'Campus Box 7305', 'Chapel Hill, NC 27599-7305', '919-843-8895 (PHONE)', '919-966-6735 (FAX)', 'Email: donald_rosenstein@med.unc.edu', 'William Wood, MD, MPH', \"3147 Physician's Office Building\", '170 Manning Drive', 'Campus Box 7305', 'Chapel Hill, NC 27599-7305', '919-966-4431 (PHONE)', '919-843-5945 (FAX)', 'Email:william_wood@med.unc.edu', 'Eliza Park, MD', \"3135 Physician's Office Building\", '170 Manning Drive', 'Campus Box 7305', 'Chapel Hill, NC 27599-7305']['LINEBERGER COMPREHENSIVE CANCER CENTER', 'CLINICAL ONCOLOGY RESEARCH PROGRAM', 'April 2017', 'UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL', '919-966-4772 (PHONE)', '919-966-6735 (FAX)', 'Email: leeza_park@med.unc.edu', 'Biostatistician', 'Allison Deal, MS', 'Biostatistics and Data Management, Rm 20-024', 'Lineberger Comprehensive Cancer Center', 'Campus Box 7295', 'Chapel Hill, NC 27599-7295', '919-966-1387 (PHONE)', '919-966-4244 (FAX)', 'Email: illison_deal@med.unc.edu', 'Sponsor: Lineberger Comprehensive Cancer Center', 'Funding Source: Rising Tide Foundation for Clinical Cancer Research', 'Version 1 Date: 6/21/2017', 'Version 2 Date: 9/14/2017', 'Version 3 Date: 11/16/2017', 'Version 4 Date: 1/10/2018', 'Version 5 Date: 9/4/2018', 'Version 6 Date: 1/10/2019', 'Version 7 Date: 8/13/2019', 'Version 8 Date: 1/14/2020', 'Version 9 Date: 3/16/2020']\n\n###\n\n", "completion": "END"}